FDA Pushes PDUFA Date Back for Tapinarof Cream, 1% (Vtama) in AD; No Safety or Efficacy Concerns Cited
The U.S. Food and Drug Administration (FDA) has extended their review of the supplemental New Drug Application (sNDA) for tapinarof cream, 1% (Vtama, Organon) as a treatment for atopic dermatitis (AD) in adults and children two years of age and older by three months. The new target action date is March 12, 2025, revised from the […]